Peroxisome proliferator-activated receptor-γ activation inhibits hepatocellular carcinoma cell invasion by upregulating plasminogen activator inhibitor-1

Cancer Science

Volumn 104, Issue 6, 2013, Pages 672-680

  Pang, Xiaojuan ^a   Wei, Yinna ^a   Zhang, Ya ^a   Zhang, Minyue ^a   Lu, Yan ^a   Shen, Pingping ^a  

^a NANJING UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

2 CHLORO 5 NITROBENZANILIDE; ESTRADIOL; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PLASMINOGEN ACTIVATOR INHIBITOR 1;

ANIMAL CELL; ARTICLE; CANCER INHIBITION; CARCINOMA CELL; CELL INVASION; CELL MIGRATION; CONTROLLED STUDY; DRUG EFFECT; GENE SILENCING; HUMAN; HUMAN CELL; LIVER CELL CARCINOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR UPREGULATION;

ANIMALS; BLOTTING, WESTERN; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; ELECTROPHORETIC MOBILITY SHIFT ASSAY; ESTRADIOL; ESTROGENS; HUMANS; LIVER NEOPLASMS; MICE; NEOPLASM INVASIVENESS; PLASMINOGEN ACTIVATOR INHIBITOR 1; PPAR GAMMA; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA INTERFERENCE; UP-REGULATION;

EID: 84878182492     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/cas.12143     Document Type: Article

References (27)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clinic 2011; 61: 69-90.
2. El-Serag HB. Epidemiology of hepatocellular carcinoma in USA. Hepatol Res 2007; 37: S88-94.
3. Worns MA, Weinmann A, Pfingst K et al. Safety and efficacy of sorafenib in patients with advanced hepatocellular carcinoma in consideration of concomitant stage of liver cirrhosis. J Clin Gastroenterol 2009; 43: 489-95.
4. Kliewer SA, Umesono K, Mangelsdorf DJ, Evans RM. Retinoid X-receptor interacts with nuclear receptors in retinoic acid, thyroid-hormone and vitamin-d3 signaling. Nature 1992; 355: 446-9.
5. Tontonoz P, Spiegelman BM. Fat and beyond: the diverse biology of PPAR gamma. Ann Rev Biochem 2008; 77: 289-312.
6. Yu J, Shen B, Chu ES et al. Inhibitory role of peroxisome proliferator-activated receptor gamma in hepatocarcinogenesis in mice and in vitro. Hepatology 2010; 51: 2008-19.
7. Ogino S, Shima K, Baba Y et al. Colorectal cancer expression of peroxisome proliferator-activated receptor γ (PPARG, PPARgamma) is associated with good prognosis. Gastroenterology 2009; 136: 1242-50.
8. Koeffler HP. Peroxisome proliferator-activated receptor γ and cancers. Clin Cancer Res 2003; 9: 1-9.
9. Toyoda M, Takagi H, Horiguchi N et al. A ligand for peroxisome proliferator activated receptor gamma inhibits cell growth and induces apoptosis in human liver cancer cells. Gut 2002; 50: 563-7.
10. Yu J, Qiao L, Zimmermann L et al. Troglitazone inhibits tumor growth in hepatocellular carcinoma in vitro and in vivo. Hepatology 2006; 43: 134-43.
11. Mueller E, Sarraf P, Tontonoz P et al. Terminal differentiation of human breast cancer through PPAR gamma. Mol Cell 1998; 1: 465-70.
12. Bren-Mattison Y, Van Putten V, Chan D, Winn R, Geraci MW, Nemenoff RA. Peroxisome proliferator-activated receptor-gamma (PPAR gamma) inhibits tumorigenesis by reversing the undifferentiated phenotype of metastatic non-small-cell lung cancer cells (NSCLC). Oncogene 2005; 24: 1412-22.
13. Duffy M, Duggan C. The urokinase plasminogen activator system: a rich source of tumour markers for the individualised management of patients with cancer. Clin Biochem 2004; 37: 541-8.
14. Rao JS. Molecular mechanisms of glioma invasiveness: the role of proteases. Nat Rev Cancer 2003; 3: 489-501.
15. Mazar AP, Henkin J, Goldfarb RH. The urokinase plasminogen activator system in cancer: implications for tumor angiogenesis and metastasis. Angiogenesis 1999; 3: 15-32.
16. Bajou K, Masson V, Gerard RD et al. The plasminogen activator inhibitor PAI-1 controls in vivo tumor vascularization by interaction with proteases, not vitronectin. J Cell Biol 2001; 152: 777-84.
17. Sawai H, Liu J, Reber HA, Hines OJ, Eibl G. Activation of peroxisome proliferator-activated receptor-gamma decreases pancreatic cancer cell invasion through modulation of the plasminogen activator system. Mol Cancer Res 2006; 4: 159-67.
18. Xu H, Wei Y, Zhang Y et al. Oestrogen attenuates tumour progression in hepatocellular carcinoma. J Pathol 2012; 228: 216-29.
19. Grommes C, Landreth GE, Heneka MT. Antineoplastic effects of peroxisome proliferator-activated receptor gamma agonists. Lancet Oncol 2004; 5: 419-29.
20. Yang K, Fan KH, Lamprecht SA et al. Peroxisome proliferator-activated receptor gamma agonist troglitazone induces colon tumors in normal C57BL/6J mice and enhances colonic carcinogenesis in Apc1638 N/+ Mlh1 +/- double mutant mice. Int J Cancer 2005; 116: 495-9.
21. Peters JM, Shah YM, Gonzalez FJ. The role of peroxisome proliferator-activated receptors in carcinogenesis and chemoprevention. Nat Rev Cancer 2012; 12: 181-95.
22. Koga H, Sakisaka S, Harada M et al. Involvement of p21WAF1/Cip1, p27Kip1, and p18INK4c in troglitazone-induced cell-cycle arrest in human hepatoma cell lines. Hepatology 2001; 33: 1087-97.
23. Annicotte JS, Iankova I, Miard S et al. Peroxisome proliferator-activated receptor gamma regulates E-cadherin expression and inhibits growth and invasion of prostate cancer. Mol Cell Biol 2006; 26: 7561-74.
24. Galli A, Ceni E, Crabb DW et al. Antidiabetic thiazolidinediones inhibit invasiveness of pancreatic cancer cells via PPARgamma independent mechanisms. Gut 2004; 53: 1688-97.
25. Fink T, Kazlauskas A, Poellinger L, Ebbesen P, Zachar V. Identification of a tightly regulated hypoxia-response element in the promoter of human plasminogen activator inhibitor-1. Blood 2002; 99: 2077-83.
26. Buchwalter G, Gross C, Wasylyk B. The ternary complex factor net regulates cell migration through inhibition of PAI-1 expression. Mol Cell Biol 2005; 25: 10853-62.
27. Choi JH, Banks AS, Kamenecka TM et al. Antidiabetic actions of a non-agonist PPARγ ligand blocking Cdk5-mediated phosphorylation. Nature 2011; 477: 477-81.